Israeli health-tech firm Genetika+ is combining the latest in stem cell technology — the growing of specific human cells — with artificial intelligence (AI) software. Established in 2018, the company says its technology can best match antidepressants to patients, to avoid unwanted side effects, and ensure that the prescribed drug works effectively. “We can characterize the right medication for each patient the first time,” states Dr. Cohen Solal, a neuroscientist, co-founder and chief executive of Israeli health-tech firm Genetika+. The technology is still under development but the company plans to launch commercially next year.
